PE20060681A1 - Composicion farmaceutica que comprende un inhibidor de tace en combinacion con un inhibidor de quinasa de src y un inhibidor del her-2 - Google Patents
Composicion farmaceutica que comprende un inhibidor de tace en combinacion con un inhibidor de quinasa de src y un inhibidor del her-2Info
- Publication number
- PE20060681A1 PE20060681A1 PE2005001187A PE2005001187A PE20060681A1 PE 20060681 A1 PE20060681 A1 PE 20060681A1 PE 2005001187 A PE2005001187 A PE 2005001187A PE 2005001187 A PE2005001187 A PE 2005001187A PE 20060681 A1 PE20060681 A1 PE 20060681A1
- Authority
- PE
- Peru
- Prior art keywords
- inhibitor
- hydroxy
- cyane
- metoxy
- butenamide
- Prior art date
Links
- 102000001332 SRC Human genes 0.000 title abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 2
- 108010087686 src-Family Kinases Proteins 0.000 title abstract 2
- 229940125497 HER2 kinase inhibitor Drugs 0.000 title 1
- 239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 title 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 3
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 abstract 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- -1 3-FLUORBENZYL Chemical class 0.000 abstract 1
- WOWKZTBVWKKGJV-UHFFFAOYSA-N 3-chloro-4-phenylmethoxyaniline Chemical compound ClC1=CC(N)=CC=C1OCC1=CC=CC=C1 WOWKZTBVWKKGJV-UHFFFAOYSA-N 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000017074 necrotic cell death Effects 0.000 abstract 1
- 230000001173 tumoral effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN COMPUESTO INHIBIDOR DE LA ENZIMA CONVERSORA DE FACTORES ALFA DE NECROSIS TUMORAL (TACE), EN UNA CANTIDAD COMPRENDIDA ENTRE 20 A 40 MG/KG, SELECCIONADOS ENTRE HIDROXIAMIDA DE ACIDO 4-(4-BUT-2-INILOXI-BENZENESULFONIL)-2,2-DIMETIL-TIOMORFOLINA-3-CARBOXILICO, (3S)-N-HIDROXI-4-({4-HIDROXI-2-BUTINIL)OXI]FENIL}SULFONIL)-2,2-DIMETIL-3-TIOMORFOLINCARBOXAMIDA, (2R)-N-HIDROXI-2-[({4-[(4-HIDROXI-2-BUTINIL)OXI]FENIL}SULFONIL)(METIL)AMINO]-3-METILBUTANAMIDA, ENTRE OTROS; B) UN INHIBIDOR DE QUINASA DE SRC TAL COMO 4-(2,4-DICLORO-5-METOXI-FENILAMINO)-6-METOXI-7-[3-(4-METIL-PIPERAZIN-1-IL)-PROPOXI]-QUINOLINA-3-CARBONITRILO EN UNA CANTIDAD COMPRENDIDA ENTRE 10 A 50 MG/KG Y C) UN INHIBIDOR DEL RECEPTOR-2 DEL FACTOR DE CRECIMIENTO EPIDERMICO HUMANO (HER-2) SELECCIONADO ENTRE (E)-N-{4-[4-(BENCILOXI)-3-CLOROANILINO]-3-CIANO-7-ETOXI-6-QUINOLINIL}-4-(DIMETILAMINO)-2-BUTENAMIDA, (E)-N-(4-{[3-CLORO-4-(1,3-TIAZOL-2-ILSULFANIL)FENIL]AMINO}-3-CIANO-7-METOXI-6-QUINOLINIL)-4-(DIMETILAMINO)-2-BUTENAMIDA, (E)-N-(4-{3-CLORO-4-[(3-FLUORBENCIL)OXI]ANILINO}-3-CIANO-7-ETOXI-6-QUINOLINIL)-4-(DIMETILAMINO)-2-BUTENAMIDA, ENTRE OTROS; EN UNA CANTIDAD COMPRENDIDA ENTRE 10 A 50 MG/KG. TAMBIEN SE REFIERE A UNA COMBINACION DE B) Y C). ESTA COMPOSICION ES UTILIZADA PARA INHIBIR LA PROLIFERACION CELULAR EN POLIQUISTOSIS RENAL.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61698104P | 2004-10-08 | 2004-10-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20060681A1 true PE20060681A1 (es) | 2006-08-28 |
Family
ID=36013658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005001187A PE20060681A1 (es) | 2004-10-08 | 2005-10-06 | Composicion farmaceutica que comprende un inhibidor de tace en combinacion con un inhibidor de quinasa de src y un inhibidor del her-2 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20060079515A1 (es) |
| EP (1) | EP1796727A2 (es) |
| JP (1) | JP2008515913A (es) |
| CN (1) | CN101102757A (es) |
| AR (1) | AR052221A1 (es) |
| AU (1) | AU2005294258A1 (es) |
| BR (1) | BRPI0516533A (es) |
| CA (1) | CA2580864A1 (es) |
| MX (1) | MX2007004001A (es) |
| PE (1) | PE20060681A1 (es) |
| TW (1) | TW200616612A (es) |
| WO (1) | WO2006042100A2 (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113952338A (zh) | 2005-02-03 | 2022-01-21 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
| CN103110948A (zh) | 2005-11-04 | 2013-05-22 | 惠氏公司 | mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合 |
| BRPI0809498A2 (pt) | 2007-04-02 | 2014-09-23 | Inst Oneworld Health | Compostos inibidores de cftr e seus usos |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| EP2278879B1 (en) * | 2008-04-21 | 2016-06-15 | PATH Drug Solutions | Compounds, compositions and methods comprising oxadiazole derivatives |
| US20090270398A1 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Pyridazine Derivatives |
| US8236838B2 (en) * | 2008-04-21 | 2012-08-07 | Institute For Oneworld Health | Compounds, compositions and methods comprising isoxazole derivatives |
| US20090264433A1 (en) * | 2008-04-21 | 2009-10-22 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Triazine Derivatives |
| US20100099677A1 (en) * | 2008-04-21 | 2010-04-22 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Thiazole Derivatives |
| EP3135285B1 (en) | 2008-06-17 | 2018-08-15 | Wyeth LLC | Antineoplastic combinations containing hki-272 and vinorelbine |
| CN105963313A (zh) | 2008-08-04 | 2016-09-28 | 惠氏有限责任公司 | 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合 |
| JP2012503005A (ja) * | 2008-09-19 | 2012-02-02 | インスティテュート フォア ワンワールド ヘルス | イミダゾール誘導体およびトリアゾール誘導体を含む、化合物、組成物ならびに方法。 |
| US8511216B2 (en) * | 2009-03-30 | 2013-08-20 | Kanzaki Kokyukoki Mfg. Co., Ltd. | Hydraulic actuator unit |
| KR20190128004A (ko) | 2009-04-06 | 2019-11-13 | 와이어쓰 엘엘씨 | 네라티닙을 이용한 유방암의 치료법 |
| US8343976B2 (en) * | 2009-04-20 | 2013-01-01 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyrazole derivatives |
| FR2947268B1 (fr) * | 2009-06-30 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
| ES2545353T3 (es) | 2010-08-26 | 2015-09-10 | Symphony Evolution, Inc. | Uso de un modulador de quinasa de tipo receptor para el tratamiento de la enfermedad poliquística del riñón |
| WO2013019169A1 (en) | 2011-08-01 | 2013-02-07 | Institute For Oneworld Health | Phosphate prodrugs |
| CA2900652C (en) | 2013-02-15 | 2021-05-04 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| KR102277833B1 (ko) | 2013-02-20 | 2021-07-14 | 칼라 파마슈티컬스, 인크. | 치료 화합물 및 그의 용도 |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| CN106061261B (zh) | 2013-11-01 | 2018-04-24 | 卡拉制药公司 | 治疗化合物的结晶形式及其用途 |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| EP3509422A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
| JP2019533641A (ja) | 2016-09-08 | 2019-11-21 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物の結晶形態およびその使用 |
| WO2018048750A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6288082B1 (en) * | 1998-09-29 | 2001-09-11 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| US6297258B1 (en) * | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| CA2357110A1 (en) * | 2001-04-11 | 2002-10-11 | American Cyanamid Company | Method for the treatment of polycystic kidney disease |
| AU2002359489B2 (en) * | 2001-11-27 | 2008-10-30 | Wyeth Holdings Corporation | 3-cyanoquinolines as inhibitors of EGF-R and Her2 kinases |
-
2005
- 2005-09-29 TW TW094133944A patent/TW200616612A/zh unknown
- 2005-10-05 US US11/243,932 patent/US20060079515A1/en not_active Abandoned
- 2005-10-06 PE PE2005001187A patent/PE20060681A1/es not_active Application Discontinuation
- 2005-10-07 BR BRPI0516533-4A patent/BRPI0516533A/pt not_active IP Right Cessation
- 2005-10-07 MX MX2007004001A patent/MX2007004001A/es not_active Application Discontinuation
- 2005-10-07 JP JP2007535836A patent/JP2008515913A/ja not_active Withdrawn
- 2005-10-07 AR ARP050104236A patent/AR052221A1/es not_active Application Discontinuation
- 2005-10-07 EP EP05804453A patent/EP1796727A2/en not_active Withdrawn
- 2005-10-07 AU AU2005294258A patent/AU2005294258A1/en not_active Abandoned
- 2005-10-07 CA CA002580864A patent/CA2580864A1/en not_active Abandoned
- 2005-10-07 CN CNA2005800338888A patent/CN101102757A/zh active Pending
- 2005-10-07 WO PCT/US2005/036122 patent/WO2006042100A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| TW200616612A (en) | 2006-06-01 |
| AR052221A1 (es) | 2007-03-07 |
| BRPI0516533A (pt) | 2008-09-09 |
| CN101102757A (zh) | 2008-01-09 |
| WO2006042100A2 (en) | 2006-04-20 |
| EP1796727A2 (en) | 2007-06-20 |
| JP2008515913A (ja) | 2008-05-15 |
| CA2580864A1 (en) | 2006-04-20 |
| US20060079515A1 (en) | 2006-04-13 |
| MX2007004001A (es) | 2007-05-11 |
| AU2005294258A1 (en) | 2006-04-20 |
| WO2006042100A3 (en) | 2007-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20060681A1 (es) | Composicion farmaceutica que comprende un inhibidor de tace en combinacion con un inhibidor de quinasa de src y un inhibidor del her-2 | |
| RU2448103C2 (ru) | Бициклические амиды как ингибиторы киназы | |
| RU2384580C2 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| CL2009001936A1 (es) | Compuestos derivados de piridazina, inhibidores de 11beta-hsd1; composicion farmaceutica; procedimiento de preparacion; y uso en el tratamiento de la diabetes, obesidad, dislipidemia, trastornos de ingestion de comida e hipertension (divisional de solicitud 1720-2006). | |
| MEP53708A (en) | 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl) -n-methyl -amino) -anilino)-1- phenyl-methylene] -6-methoxycarbonyl -2-indolinone -monoethanesulphonate and the use thereof as a pharmaceutical composition | |
| SG153851A1 (en) | N-(1-(1-benzyl -4-phenyl-1h-imidazol-2-yl)-2,2-dymethylpropyl)benzamide derivatives and related compounds as kinesin spindle protein (ksp) inhibitors for the treatment of cancer | |
| MX2010006260A (es) | Composiciones orales de abt-263 para tratar cancer. | |
| SG154432A1 (en) | Quinazolinedione derivatives as parp inhibitors | |
| DE60332433D1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| DE60332604D1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| DE602004014117D1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
| EA200701257A1 (ru) | Пирролопиразолы в качестве сильнодействующих ингибиторов киназы | |
| DOP2013000169A (es) | Compuesto para uso en el tratamiento de la artritis | |
| ATE450530T1 (de) | Zusammensetzungen zur verwendung als protein- kinase-inhibitoren | |
| ATE365733T1 (de) | Zusammensetzungen brauchbar als protein-kinase- inhibitoren | |
| SE0301888D0 (sv) | New use VII | |
| EA200870376A1 (ru) | Бензотиазолы, обладающие активностью по отношению к h3-рецептору гистамина | |
| CY1111197T1 (el) | Tριαζολες χρησιμες ως αναστολεις πρετεϊνικων κινασων | |
| EA200901514A1 (ru) | Новая сольватная и кристаллическая форма производных карбамоилциклогексана | |
| BR0211274A (pt) | Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase | |
| AR044155A1 (es) | Combinacion que comprende 2- metilpropanotioato de s- [2-({[ 1- (2 - etilbutil) ciclohexil] carbonil} amino) fenilo ] y un inhibidor de hmg coa reductasa | |
| ATE364044T1 (de) | 5ht2c rezeptor agonisten zur behandlung von diabetes und fettleibigkeit | |
| CL2011003138A1 (es) | N-(protegido- n-(3-metoxi-5-metilpirazon-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridino-3-sulfonamida y su proceso de preparacion. | |
| DE60306546D1 (de) | Entzündungshemmende 3-arylthio-3-thiazolylalkylamine | |
| SE0302756D0 (sv) | Novel Compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |